TL;DR
As hemodialysis patients live longer, cancer is becoming a more common comorbidity. This study investigated whether doctors adjust dialysis-related care for patients with cancer. While most aspects of care remained similar, patients with recent cancer treatment received higher doses of erythropoiesis-stimulating agents (ESAs).
What Problem Does This Paper Address?
The increasing longevity of patients undergoing hemodialysis (HD) means that cancer is becoming a more prevalent co-occurring condition. This raises questions about how to best manage these complex patients. Specifically, it's unclear if physicians alter their standard dialysis practices – which encompass anemia management, mineral and bone metabolism, nutrition, and the dialysis treatment itself – when a patient also has cancer. This is particularly relevant for anemia management, as guidelines for cancer patients often caution against ESA use due to potential adverse effects on cancer progression, creating a potential conflict with standard HD anemia protocols. This study aims to clarify current practice patterns in Japan to inform future care improvements.
Methods
The researchers conducted a cross-sectional analysis using baseline data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS) phase 4, which collected data from 2009-2011. They evaluated 2153 HD patients, categorizing them into three groups based on cancer status: no cancer, cancer with recent treatment (defined as treatment within the year prior to baseline), and cancer without recent treatment.
The study assessed several key areas of dialysis-related practice:
- Anemia Management: This included measuring hemoglobin (Hb) and ferritin levels, tracking the use and dosage of erythropoiesis-stimulating agents (ESAs) like epoetin, darbepoetin, and epoetin beta pegol, calculating the erythropoietin resistance index (ERI), and noting the use of intravenous iron and blood transfusions.
- Mineral and Bone Metabolism Disorder (MBD) Management: This involved analyzing serum levels of phosphorus, calcium, and intact parathyroid hormone, as well as the use of phosphate binders, vitamin D receptor activators, and cinacalcet.
- Nutritional Management: Assessed through serum albumin levels and normalized protein catabolic rate (nPCR).
- Dialysis Treatment: Evaluated using indicators such as single pool Kt/V, dialysis session duration, blood flow rate, and intradialytic weight loss.
Statistical analyses included descriptive statistics, ANOVA, and chi-squared tests to compare groups. To account for the clustering effect of dialysis facilities, generalized estimating equations (GEE) were used. Analyses were adjusted for age and other comorbidities in "fully adjusted" models.
Datasets
The study utilized data from the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS) phase 4. This is an existing, large-scale observational study of hemodialysis patients in Japan. No new datasets were introduced.
Key Insights and Ideas
- ESA Use is Higher in Cancer Patients: The most significant finding is the increased use of ESAs in HD patients with recent cancer treatment. This suggests physicians may be prioritizing maintaining target hemoglobin levels, potentially to avoid transfusions, even in the context of cancer.
- No Major Differences in MBD, Nutrition, or Dialysis: Despite cancer being a complex condition, the study found no statistically significant differences in how MBD, nutritional status, or core dialysis treatment parameters were managed between cancer patients and those without cancer. This implies a general standardization of these aspects of care.
- Physician Practices Aren't Heavily Modulated by Cancer Status (Except for ESA): The overall finding suggests that, for the most part, physicians are not significantly altering their dialysis-related practices based on a patient's cancer status, with the notable exception of ESA dosing.
- Baseline Characteristics Differ: Patients with cancer were generally older and more likely to be female, which aligns with general epidemiological trends for cancer risk.
Key Results
- ESA Dose: Patients with recent cancer treatment received a higher mean ESA dose, with a multivariable-adjusted mean difference of 5.4 x 10³ IU/L/month compared to patients without cancer.
- Hemoglobin Levels: Hemoglobin levels were similar across all cancer status groups (mean around 10.2-10.4 g/dL).
- Phosphorus and Calcium: Levels of phosphorus and calcium were also similar between groups.
- Nutritional Status: Serum albumin and nPCR were comparable across all groups.
- Dialysis Treatment: Indicators like Kt/V, dialysis time, blood flow rate, and intradialytic weight loss showed no significant differences between groups.
- Patient Population: Out of 2153 HD patients, 84 (3.9%) had cancer without recent treatment, and 68 (3.2%) had cancer with recent treatment.
Limitations and Future Work
The authors acknowledge several limitations:
- Facility-Based HD Only: The study only included patients in long-term facility-based HD, excluding peritoneal dialysis, home dialysis, and predialysis patients.
- Japanese Population: The findings are specific to Japanese HD patients and may not be generalizable to other populations.
- Lack of Cancer Activity Data: The study did not capture crucial details about cancer activity, such as whether it was active or in remission, cancer type, or stage. This limits the ability to understand the impact of active disease.
- Small Cancer Cohort: The relatively small number of cancer patients (n=152) limited the power to perform detailed analyses, particularly regarding associations between practice patterns and clinical outcomes.
- Physician/Facility Dependence: The evaluation of cancer presence relied on physician and facility reporting, which could introduce bias.
- Nutritional Indicators: The study used serum albumin and nPCR, but other nutritional indicators might provide a more comprehensive picture.
Future work should focus on larger, multi-national studies with more detailed cancer information to better understand the nuances of managing HD patients with cancer. Further research is also needed to explore the rationale behind increased ESA use in this population and its potential impact.
Summary updated